18 completed, 2 active not recruiting, 1 recruiting, 1 terminated. 23 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 18, Active not recruiting 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow RSV Infection: new trials by email Literature Review of RSV Infection trials Research Report on RSV Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity Study of SCB-1019T in Children low dose SCB-1019T, adjuvanted low dose SCB-1019T, high dose SCB-1019T - RSV Infection | Phase 1 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2025-10-01 | 2024-12-31 | |
| Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults SCB-1019T, SCB-1022, SCB-1033 - RSV Infection, Human Metapneumovirus Infection | Phase 1 / Phase 2 | Active not recruiting | Clover Biopharmaceuticals AUS Pty | 612 | 2025-06-18 | 2026-10-26 |
| Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults Candidate vaccine, SCB-1019T, AREXVY, placebo - RSV Infection | Phase 1 | Recruiting | Clover Biopharmaceuticals USA, LLC | 160 | 2025-03-21 | 2025-05-14 |
| A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants EDP-323, Midazolam, Caffeine - RSV Infection, Drug Drug Interaction | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 24 | 2025-03-13 | 2025-07-01 |
| A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. EDP-323, Itraconazole, carbamazepine - RSV Infection, Drug Drug Interaction (DDI) | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 48 | 2025-01-27 | 2025-07-01 |
| Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years RSV/hMPV vaccine dose A1, RSV/hMPV vaccine dose A2, RSV/hMPV vaccine dose A3 - RSV Infection, hMPV | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 385 | 2024-10-09 | 2025-11-20 |
| A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults LYB005 low dose without adjuvant, LYB005 middle dose without adjuvant, LYB005 high dose without adjuvant - Respiratory Syncytial Virus (RSV), RSV Infection | Phase 1 | Active not recruiting | Guangzhou Patronus Biotech Co., Ltd. | 84 | 2024-07-31 | 2025-03-13 |
| A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo - RSV Infection, QTc Interval | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 72 | 2024-07-15 | 2025-07-28 |
| A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV XW001, Placebo - RSV Infection | Phase 1 / Phase 2 | Completed | Hangzhou Sciwind Biosciences Co., Ltd. | 61 | 2023-04-20 | 2025-08-17 |
| A Study of EDP-323 in Healthy Subjects EDP-323, Placebo - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 82 | 2022-09-29 | 2023-09-01 |
| Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age RSV LID/ΔM2-2/1030s, Placebo - RSV Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 81 | 2022-03-16 | 2026-07-20 |
| Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults RSM01, Placebo - RSV Infection | Phase 1 | Completed | Gates Medical Research Institute | 56 | 2021-11-16 | 2024-05-20 |
| Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects EDP-938, Fluconazole - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 24 | 2021-03-12 | 2021-05-04 |
| Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects EDP-938, Tacrolimus, Dabigatran - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 89 | 2020-07-08 | 2021-10-13 |
| Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects EDP-938, Itraconazole, Rifampin - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 72 | 2018-11-29 | 2019-06-14 |
| Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects EDP-938, Cyclosporine, Prednisone - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 48 | 2018-11-02 | 2019-02-12 |
| Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children RSV 6120/∆NS1, RSV 6120/F1/G2/∆NS1, Placebo - RSV Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2018-06-29 | 2026-02-13 |
| A Study of EDP-938 in Healthy Subjects EDP-938, Placebo - RSV Infection | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 90 | 2017-12-07 | 2018-10-10 |
| Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children RSV 6120/∆NS2/1030s, Placebo - RSV Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 45 | 2017-10-13 | 2024-12-11 |
| ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers ALX-0171 - Healthy, RSV Infection | Phase 1 | Completed | Ablynx, a Sanofi company | 44 | 2013-05-01 | 2018-07-13 |
Showing 20 of 23. Sign in to see all of them.
Respiratory Syncytial Virus Infections (23) · Paramyxoviridae Infections (1)
Infections (23) · Mononegavirales Infections (23) · Pneumovirus Infections (23) · RNA Virus Infections (23) · Virus Diseases (23) · Paramyxoviridae Infections (22)
EDP-938 (6) · Fluconazole (2) · Itraconazole (2) · Midazolam (2) · Quinidine (2) · Rosuvastatin Calcium (2) · gontivimab (2) · Adjuvants, Pharmaceutic (1) · Caffeine (1) · Carbamazepine (1) · Cyclosporine (1) · Dabigatran (1) · Moxifloxacin (1) · Prednisone (1) · Rifampin (1)
Enanta Pharmaceuticals, Inc (9) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Ablynx, a Sanofi company (2) · Clover Biopharmaceuticals AUS Pty (2) · Clover Biopharmaceuticals USA, LLC (1) · Gates Medical Research Institute (1) · Gilead Sciences (1) · Guangzhou Patronus Biotech Co., Ltd. (1) · Hangzhou Sciwind Biosciences Co., Ltd. (1) · MedImmune LLC (1) · Sanofi Pasteur, a Sanofi Company (1)
United States (15) · Australia (4) · Belgium (1) · China (1) · Netherlands (1) · United Kingdom (1)
Ruth A. Karron, MD (3) · Christina Chang, M.D (1) · Christopher D Rook, MD (1) · Hanmin Liu, Dr (1) · Hasan Jafri, MD (1) · Josefin-Beate Holz, MD (1) · Qin Yu (1) · Seth Toback, M.D. (1) · Steven De Bruyn, MD (1)